Management of hepatitis C in HIV and/or HBV co-infected patients.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Best practice & research. Clinical gastroenterology

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bpg.2012.09.007PMID 23199509
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cited by this paper
• Review and management of drug interactions with boceprevir and telaprevir

  2012cited by this paper
• Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

  2012cited by this paper
• Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.

  2012cited by this paper
• Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.

  2012cited by this paper
• Telaprevir in combination with peginterferon Alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis

  2012cited by this paper
• Management and Treatment of Chronic Hepatitis C in HIV Patients

  2012cited by this paper
• 50 BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN FOR THE TREATMENT OF HCV/HIV CO-INFECTED PATIENTS: END OF TREATMENT (WEEK 48) INTERIM RESULTS

  2012cited by this paper
• 8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)

  2012cited by this paper
• Liver Transplantation in HIV Patients

  2012cited by this paper
• Treatment failure with new hepatitis C drugs

  2012cited by this paper
• Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.

  2012cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

  2012cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B.

  2011cited by this paper
• Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference.

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Predicted Effect of Direct Acting Antivirals in the Current HIV–HCV-Coinfected Population in Spain

  2011cited by this paper
• Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.

  2011cited by this paper
• An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection

  2011cited by this paper
• HIV/hepatitis C coinfection natural history and disease progression.

  2011cited by this paper
• Response-guided telaprevir combination treatment for hepatitis C virus infection.

  2011cited by this paper
• Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

  2011cited by this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2011cited by this paper
• Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection.

  2010cited by this paper
• Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients

  2010cited by this paper
• Acute hepatitis C in HIV-infected individuals – recommendations from the NEAT consensus conference

  2010cited by this paper
• Survival of HIV-infected patients with compensated liver cirrhosis

  2010cited by this paper
• Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy

  2010cited by this paper
• A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis

  2010cited by this paper
• High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

  2010cited by this paper
• Rate and Predictors of Success in the Retreatment of Chronic Hepatitis C Virus in HIV/Hepatitis C Virus Coinfected Patients With Prior Nonresponse or Relapse

  2010cited by this paper
• Viral hepatitis and HIV co-infection.

  2010cited by this paper
• Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

  2010cited by this paper
• Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

  2010cited by this paper
• Acute hepatitis C and HIV coinfection.

  2009cited by this paper
• Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

  2009cited by this paper
• Diagnosis, management, and treatment of hepatitis C: An update

  2009cited by this paper
• Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis

  2009cited by this paper
• Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

  2009cited by this paper
• Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection.

  2009cited by this paper
• Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells.

  2009cited by this paper
• Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

  2009cited by this paper
• Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference

  2009cited by this paper
• Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection

  2008cited by this paper
• Viral hepatitis and HIV coinfection.

  2008cited by this paper
• Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment

  2008cited by this paper
• The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis

  2008cited by this paper
• Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial

  2007influential reference
• Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.

  2007influential reference
• Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.

  2007cited by this paper
• Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis

  2007cited by this paper
• Liver cirrhosis in HIV‐infected patients: prevalence, aetiology and clinical outcome

  2007cited by this paper
• Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.

  2007cited by this paper
• Liver Fibrosis Stage and HCV Genotype Distribution in HIV–HCV Coinfected Patients with Persistently Normal Transaminases

  2007cited by this paper
• Therapeutic issues in HIV/HCV-coinfected patients

  2007cited by this paper
• Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

  2006cited by this paper
• AIDS Res Hum Retroviruses

  2006cited by this paper
• Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients

  2006cited by this paper
• Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

  2006cited by this paper
• Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity

  2006cited by this paper
• Histological response to pegIFNα-2a (40KD) plus ribavirin in HIV–hepatitis C virus co-infection

  2006cited by this paper
• Epidemiology, natural history, and treatment of hepatitis B virus and hepatitis C virus coinfection.

  2006cited by this paper
• Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

  2006cited by this paper
• Impact of Ribavirin Exposure on Early Virological Response to Hepatitis C Therapy in HIV-Infected Patients with Chronic Hepatitis C

  2005cited by this paper
• Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection

  2005cited by this paper
• Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C

  2005cited by this paper
• Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

  2005cited by this paper
• Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients

  2005cited by this paper
• Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.

  2005cited by this paper
• Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study

  2005cited by this paper
• Humoral immune response in acute hepatitis C virus infection.

  2005cited by this paper
• Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection.

  2004cited by this paper
• Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

  2004cited by this paper
• Long-Term Follow-Up of HIV-Infected Patients with Chronic Hepatitis C Virus Infection Treated with Interferon-Based Therapies

  2004cited by this paper
• Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

  2004cited by this paper
• Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study.

  2004cited by this paper
• Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

  2004cited by this paper
• Testing for Hepatitis C Virus Infection Should Be Routine for Persons at Increased Risk for Infection

  2004cited by this paper
• Hepatitis C Virus (HCV) Relapses after Anti-HCV Therapy Are More Frequent in HIV-Infected Patients

  2004cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.

  2003cited by this paper
• Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

  2003cited by this paper
• Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy

  2003cited by this paper
• Extending combination therapy with peginterferon alfa‐2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases

  2003cited by this paper
• Liver Biopsy in HIV-Infected Patients with Chronic Hepatitis C: Pros and Cons

  2002cited by this paper
• Treating hepatitis C in methadone maintenance patients: an interim analysis.

  2002cited by this paper
• Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C

  2000cited by this paper
• Impact of acute hepatitis B virus superinfection on chronic hepatitis c virus infection

  2000cited by this paper
• The natural history of hepatitis C virus infection: host, viral, and environmental factors.

  2000cited by this paper
• Relevance of inapparent coinfection by hepatitis B virus in alpha interferon‐treated patients with hepatitis C virus chronic hepatitis

  1997cited by this paper
• Prevalence and significance of hepatitis C viremia in chronic active hepatitis B.

  1994cited by this paper
• The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B.

  1994cited by this paper
• Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection.

  1993cited by this paper
• American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury

  1960cited by this paper

• SEROPREVALENCE OF HEPATITIS B VIRUS INFECTION AMONG HIV INFECTED INDIVIDUALS IN UYO, AKWA IBOM STATE, NIGERIA

  2021cites this paper
• 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

  2018cites this paper
• Detection of the Prevalence of HBV/HCV Coinfection in Anti-HCV-Positive Samples

  2018cites this paper
• New hepatitis C therapies for special patient populations

  2016cites this paper
• Delta hepatitis: new approaches to therapy

  2016cites this paper
• KASL clinical practice guidelines: management of hepatitis C

  2016cites this paper
• DETECTION OF STAT-1 IN PATIENTS CO-INFECTED WITH HEPATITIS B AND C RESISTANT TO INTERFERON

  2016cites this paper
• Recent advances in micro/nanotechnologies for global control of hepatitis B infection.

  2015influential citation
• Viral hepatitis and human immunodeficiency virus co-infections in Asia.

  2015cites this paper
• Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection

  2015cites this paper
• Emerging Challenges in Managing Hepatitis B in HIV Patients

  2015cites this paper
• Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

  2015cites this paper
• A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.

  2015cites this paper
• KASL clinical practice guidelines: Management of Hepatitis C

  2014cites this paper
• Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus‐infected patients

  2014cites this paper
• Epidemiologia da coinfecção por HIV/HCV em um hospital escola de Catanduva, São Paulo – Brasil

  2014cites this paper
• IL‐34 and macrophage colony‐stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells

  2014cites this paper
• Treatment of patients with dual hepatitis B and C: a step in the right direction

  2013cites this paper
• Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals

  2013cites this paper